Partner:

Asset Type:

Partner Background:

Partnership Details:

Partner:

Asset Type:

Immuno-Oncology

Partner Background:

Yuhan Corporation is one of the largest Korean pharmaceutical companies, founded over 80 years ago

Partnership Details:

Joint Venture named ImmuneOncia Therapeutics, LLC

Focused on developing and commercializing a number of immune checkpoint antibodies for hematological malignancies and solid tumors

Partner:

Asset Type:

Immuno-Oncology

Partner Background:

Lee’s Pharm is a public biopharma company with over 20 years of operation in China and currently markets 14 products in the PRC

Partnership Details:

Sorrento has licensed exclusive rights to Lee’s Pharm to develop and commercialize the fully human anti-PD-L1 mAb STI-A1014 for the greater Chinese market

Partner:

Asset Type:

Cellular Therapy

Partner Background:

Celularity is a spin-off from Celgene Corporation focusing on placenta-derived and cord-blood derived cells therapies

Partnership Details:

Equity Investment and Board Representation

Partner:

Asset Type:

Immuno-oncology

Partner Background:

MABPHARM is a biopharma company focusing on the R&D and production of new drugs and “Biobetters” for cancer and autoimmune diseases

Partnership Details:

Sorrento has an exclusive license to commercialize four Biobetters that have completed Phase 3 studies in China for the North American, European and Japan markets